Compounded Semaglutide: Base Form vs. Salt Form — What the Science Says

Q: Is semaglutide acetate the same as semaglutide base?

Pharmacologically, semaglutide acetate and semaglutide base release the same active semaglutide peptide once dissolved in the body. A salt form is created when the parent molecule — in this case the semaglutide peptide — combines with a counterion (acetate, in this case). Upon dissolution in aqueous body fluids, the salt dissociates and the active molecule is the same regardless of which salt was used. This is a standard principle in pharmaceutical chemistry and is why FDA and pharmacologists generally treat a drug and its salts as the same active ingredient. Where base and salt forms can differ is in physical properties such as solubility, stability, and hygroscopicity — differences that matter for compounding quality but not for the identity of the active molecule.

Q: Why did the FDA object to semaglutide sodium and acetate in compounding?

FDA's primary argument was that the drug shortage list covered semaglutide — meaning the free base or free acid form of the peptide as designated in the compendium — and that semaglutide sodium and semaglutide acetate were technically distinct chemical entities not covered by the shortage exception. This was partly a nomenclature and regulatory classification argument. FDA also relied on the broader position that its copy prohibition applies to the active ingredient regardless of counterion, and that drawing a regulatory distinction between the base and its salts was contrary to established pharmaceutical science and FDA regulatory practice. Some compounders used the salt-form distinction as a legal argument for continuing to compound after semaglutide left the shortage list; FDA rejected this position.

Between 2022 and 2025, millions of Americans used compounded semaglutide. A significant portion of that compounded product was made not from semaglutide in its base (free acid) form, but from semaglutide sodium or semaglutide acetate — salt forms of the same molecule. This distinction, largely invisible to patients, became the center of a genuine scientific and regulatory dispute that has been badly garbled in online communities.

Reddit threads declared compounded semaglutide made from salts "fake" or "not real semaglutide." Some compounders argued the opposite — that using salt forms was actually a way to continue legally after the shortage exception expired. The FDA had its own position. And pharmacologists, reading the same molecular data, generally came to a different conclusion than either side of the regulatory fight.

This guide walks through what the chemistry actually says, what the legal dispute was really about, and how to interpret the controversy if you were a patient who used compounded semaglutide.

Important framing: This guide is written by an attorney with an interest in accurate science communication — not as an advocate for compounders or for FDA. The base vs. salt debate has both a pharmacological dimension and a legal/regulatory dimension, and the two are not the same question. Getting them confused is the source of most of the misinformation.

Why This Matters and Why It's Confusing

The confusion arises because the base vs. salt question is actually two separate questions being argued simultaneously:

The scientific question: Does the salt form (sodium, acetate) make a functional difference to the patient — do they get the same active semaglutide molecule and the same clinical effects?
The regulatory question: What substance did the FDA drug shortage list cover, and does using a salt form change the legal analysis?

The answer to the scientific question and the answer to the regulatory question are, in important respects, different — and understanding that distinction is the key to reading this whole controversy accurately.

On the scientific question, the pharmacological evidence is fairly straightforward and broadly agreed upon: salt forms of a peptide drug dissolve in body fluids and release the same active molecule. The functional semaglutide a patient receives is not materially different based on whether the starting material was the base or a salt.

On the regulatory question, the analysis is more technical and contested. FDA's position was that the shortage list covered a specific substance designation — semaglutide in its base form as listed in the compendium — and that salt forms were legally distinct entities. Compounders argued the opposite. Courts weighed in with varying results. And by 2026, the broader semaglutide compounding fight was largely resolved, though not primarily on the salt-form question.

Basic Pharmaceutical Chemistry: Base Forms and Salt Forms

Most pharmaceutical molecules can exist in a "free base" form and one or more "salt" forms. Understanding what these terms mean requires a brief chemistry primer — but not a complicated one.

The Basics of Drug Salt Chemistry

A drug molecule typically has at least one acidic or basic functional group — a site that can either donate or accept a proton (a hydrogen ion). In its "free" form, this site is in its neutral, un-ionized state. That neutral form is the "free base" or "free acid" form of the drug, depending on its chemistry.

A salt is formed when that functional group is paired with a counterion — typically an acid (for basic drugs) or a base (for acidic drugs). For example: if the drug molecule has an acidic site (like many peptides), combining it with sodium hydroxide yields the sodium salt. Combining it with acetic acid yields the acetate salt. The resulting compound is chemically distinct in the solid state — it has a different molecular formula and different physical properties.

The critical pharmacological point: once the salt is dissolved in aqueous solution — as happens within seconds of injection into subcutaneous tissue — the counterion dissociates from the drug molecule. What remains in solution is the active drug molecule, which is the same regardless of whether you started with the free base, the sodium salt, or the acetate salt.

This is why FDA's regulatory framework, and standard pharmaceutical science, treats a drug and its salts as the same active ingredient for purposes of bioequivalence, approval, and regulatory classification. The identity of the active pharmaceutical ingredient (API) is defined by the parent molecule, not the counterion.

This principle applies throughout pharmacology. Fluoxetine hydrochloride (Prozac) and fluoxetine base are the same drug. Metformin hydrochloride is the same active ingredient as metformin base. Countless FDA-approved drugs are formulated as salts of the active molecule — this is often done because the salt form has better solubility, stability, or manufacturability than the free base. The therapeutic molecule delivered to the patient is the same.

Semaglutide is a GLP-1 receptor agonist peptide — a relatively large molecule by pharmaceutical standards, with 31 amino acids and a fatty acid chain. Like other peptides, it has multiple ionizable sites. Semaglutide base, semaglutide sodium, and semaglutide acetate all contain the identical peptide backbone and fatty acid modification that constitute the active molecule. The difference is only in what counterion is associated with the peptide in the solid, pre-dissolution state.

Why Ozempic and Wegovy Use Specific Formulation Parameters

The FDA-approved New Drug Applications for Ozempic (semaglutide for type 2 diabetes) and Wegovy (semaglutide for chronic weight management) specify precise formulation parameters: the exact form of semaglutide, the excipients, the pH of the solution, the buffer system, and the delivery mechanism. This specificity is not arbitrary — it reflects the formulation development that Novo Nordisk did to optimize stability, bioavailability, and tolerability in a subcutaneous injection product.

Novo Nordisk's branded formulations use specific buffer and pH conditions that reflect the full formulation chemistry of the approved product. The NDA approval covers that complete formulation, not just the active molecule in isolation. A compounding pharmacy reproducing the general effect of semaglutide is not required to exactly replicate that formulation — but the formulation parameters that Novo Nordisk optimized through clinical development are the basis for the bioavailability and tolerability data in the approved labeling.

Researchers and formulators have noted that semaglutide, like other peptide drugs, has physical properties — solubility, aggregation behavior, stability over time and temperature — that depend on the ionic environment. A compounded preparation using semaglutide acetate in a different buffer system than Novo Nordisk's approved formulation may have different physical stability characteristics, even if the active molecule is functionally equivalent at the injection site.

This matters for compounding quality — but it is a formulation quality question, not a "different drug" question.

The FDA's Position During the Shortage Period

When semaglutide products were on the FDA drug shortage list (from approximately 2022 through early 2025), both 503A pharmacies and 503B outsourcing facilities could legally compound preparations containing semaglutide under the drug shortage exception in the Federal Food, Drug, and Cosmetic Act.

The dispute over salt forms became legally significant in two related contexts:

First: What did the shortage list actually cover?

FDA's position was that the shortage list designation referred to semaglutide in its free acid / base form — the form in which the active ingredient is identified in the United States Pharmacopeia (USP) and other compendial references. Some compounders argued that the shortage list covered semaglutide broadly, including salt forms. FDA's reading was the narrower one: the shortage list covered a specific pharmacopeial designation, and deviations from that designation were not covered.

This was a technical statutory and regulatory interpretation question — the kind of argument that produces litigation, which it did.

Second: Can a salt form escape the "essentially a copy" prohibition?

A separate but related argument surfaced as semaglutide products were being removed from the shortage list. Some compounders argued that because they were using semaglutide sodium or semaglutide acetate — technically distinct chemical entities from the semaglutide free base in Ozempic — their preparations were not "essentially a copy" of the FDA-approved drug and therefore not subject to the copy prohibition even after the shortage exception expired.

FDA explicitly rejected this argument. The agency's position, consistent with its longstanding regulatory practice, was that a drug and its pharmacologically equivalent salt forms are the same active ingredient for purposes of the copy prohibition. Drawing a legal distinction between semaglutide base and semaglutide sodium, FDA argued, contradicted both established pharmaceutical science and the established meaning of "active ingredient" in FDA regulatory law. Using a different counterion does not transform a copy into a distinct drug.

FDA's Position

The shortage list covered semaglutide in its compendially designated form (free acid / base)
Salt forms are not separately listed substances on the shortage list
A drug and its salts are the same active ingredient under FDA regulatory law
The copy prohibition applies to the active ingredient, not the counterion
Using semaglutide sodium or acetate does not create a distinct, non-copied drug

Compounders' Counterargument

Semaglutide sodium and semaglutide acetate are distinct CAS-registered chemical entities
The shortage list text covered semaglutide broadly, including salt forms
Salt forms are standard compounding practice across the industry
The active molecule is functionally identical — no safety or efficacy distinction
FDA's position was a nomenclature argument, not a pharmacological one

It is worth noting that both sides had defensible positions within their own framing. The compounders were not wrong that the functional active molecule is the same. FDA was not wrong that its regulatory framework treats drug identity at the level of the parent molecule, not the counterion. These two positions are not actually inconsistent — they operate on different levels of analysis.

What the Court Challenges Found

The base vs. salt question was not the primary issue litigated in the major compounding cases of 2024–2026, but it appeared in the broader regulatory dispute over semaglutide compounding access.

2022–2024

Shortage Period — Compounding Broadly Available Semaglutide products on FDA shortage list. 503A and 503B facilities compound both base and salt forms under the shortage exception. The chemical form used by individual pharmacies varies by supplier availability.
Early 2025

FDA Removes Semaglutide from Shortage List FDA determines the shortage has resolved and removes Ozempic and Wegovy from the shortage list. The legal basis for 503B bulk compounding of semaglutide largely ends. FDA issues guidance and begins enforcement signaling.
2024–2025

Outsourcing Facilities Association Litigation Contested The Outsourcing Facilities Association (OFA) and allied parties challenge FDA's shortage determination and enforcement posture in federal court. Cases raise procedural and substantive questions about FDA's authority to remove drugs from the shortage list and enforce against compounders. The base vs. salt issue appears in the legal arguments over what the shortage list covered and whether salt-form compounding was covered.
2024–2025

Tirzepatide Litigation — Parallel Track Evolving A separate line of cases involves tirzepatide compounding. The Outsourcing Facilities Association and individual 503B facilities challenge FDA's enforcement on tirzepatide. Courts in these cases address similar procedural questions — whether FDA followed proper rulemaking procedures in its shortage determinations and enforcement guidance.
2025–2026

Landscape Shifts Against Widespread 503A Compounding Largely Resolved By 2026, most 503A pharmacies no longer compound semaglutide under any remaining exception. The combined effect of shortage list removal, FDA enforcement, and litigation outcomes largely ended the commercial-scale compounded semaglutide market. The salt-form legal argument did not prevail as an independent basis for continued compounding.

Courts considering these disputes generally addressed the procedural questions about FDA authority — whether FDA followed the right process — rather than adjudicating the pharmacological question of whether semaglutide base and its salts are the same active ingredient. The pharmacological question was largely not in dispute in the litigation; what courts evaluated was whether FDA had statutory authority for its shortage determinations and enforcement actions, and whether it had followed required procedures.

What the litigation was actually about: The legal cases challenging FDA's semaglutide compounding enforcement were primarily about administrative procedure — did FDA follow proper notice-and-comment rulemaking, did it correctly apply the shortage list statute, did it have authority to direct enforcement against 503A pharmacies in the way it did. These are important questions, but they are not pharmacological questions. A court ruling in favor of a compounder on a procedural ground would not mean the FDA was wrong about the science.

What the Science Actually Says About Patient Impact

Setting the regulatory dispute aside, what does the available pharmacological evidence say about whether patients who received semaglutide acetate or semaglutide sodium got functionally equivalent semaglutide?

The scientific consensus among pharmacologists is that the answer is yes — the active molecule is the same after dissolution. This position is not a fringe view or a compounder talking point; it reflects how pharmaceutical scientists understand drug salt chemistry. Salt forms of a peptide drug release the parent peptide upon dissolution, and the parent peptide is what acts on GLP-1 receptors.

Researchers studying compounded GLP-1 preparations have noted, however, that several factors beyond the salt form affect what a patient actually receives:

Concentration accuracy

Perhaps the most significant quality concern with compounded semaglutide was not the salt form but the concentration. Independent laboratory testing of compounded semaglutide preparations by researchers and journalists found meaningful variation in actual semaglutide concentration relative to labeled concentration. A preparation labeled as 2.5 mg/0.5 mL might contain significantly more or less than that amount. This matters for both efficacy (underdosing means less effect) and safety (overdosing increases side effect risk). The salt form is irrelevant to concentration accuracy — that is a quality control problem.

Sterility and contamination

Subcutaneous injectable preparations must be sterile. The sterility risk in compounded injectables is not related to the drug's salt form; it is related to the compounding facility's aseptic technique, environmental controls, and testing protocols. The 2012 fungal meningitis outbreak that prompted the DQSA and created the 503B pathway was a sterility failure, not a salt-form issue. This risk is meaningfully reduced in 503B facilities subject to cGMP requirements, and more variable in 503A pharmacies.

Stability and shelf life

Different salt forms of a peptide can have different physical stability characteristics — how quickly they degrade, how sensitive they are to temperature or light, how prone they are to aggregation. Compounded preparations may not have the same validated stability data that Novo Nordisk developed for its branded formulations. A preparation that has degraded due to inadequate storage or an unstable formulation may be less potent regardless of what salt form it started as.

Excipient compatibility

The excipients in a compounded preparation — the inactive ingredients that make up the buffer, the pH, the preservative system — interact with the active molecule. A compounded preparation using semaglutide acetate in a buffer system not optimized for that form may have different physical behavior than one using a sodium salt in a compatible buffer. These differences are pharmacologically secondary — they affect the pre-dissolution environment, not the active molecule delivered — but they can matter for the practical stability and comfort of the preparation.

The Real Quality Questions for Compounded Semaglutide

Was the concentration accurate? Was third-party Certificate of Analysis (CoA) testing performed on the batch, and did it confirm labeled concentration?
Was the preparation sterile? Was it compounded in a facility with documented aseptic technique and sterility testing?
Was the formulation stable? Was it properly stored, within appropriate dating, and formulated with validated stability data?
Was the pharmacy licensed and audited? Was it a registered 503B facility with FDA inspection history, or a 503A pharmacy with documented quality practices?
Was the salt form semaglutide sodium, acetate, or base? This matters much less than the four questions above.

What This Means for Patients Who Used Compounded Semaglutide

If you used compounded semaglutide during the shortage period — from a telehealth platform, a compounding pharmacy program, or a prescriber who worked with a compounding facility — the base vs. salt debate probably creates more anxiety than the pharmacological evidence warrants.

The "sketchy semaglutide" framing that circulates in patient communities is an overcorrection to a real but different concern. The actual concern is quality variation across compounding pharmacies, which is a genuine issue. But the specific worry that semaglutide sodium or semaglutide acetate is somehow "not real semaglutide" or functionally inferior because of the salt form is not supported by the pharmacological science.

A more calibrated framing: if you received compounded semaglutide from a reputable pharmacy — one that provided third-party CoA documentation, was a licensed 503A pharmacy or registered 503B facility, used established compounding practices, and had a track record without documented contamination or concentration failures — the available evidence suggests you received functional semaglutide. Whether that pharmacy used the base or a salt form is not the relevant quality variable.

If, on the other hand, you received a preparation from a pharmacy with no documentation, no CoA, unclear licensing status, or from a source that shipped internationally or operated in a regulatory gray area — the concern is the quality and safety of that specific operation, not the salt form per se.

If you experienced unexpected side effects or inadequate efficacy with compounded semaglutide: These experiences are worth discussing with your prescriber. They are more likely attributable to concentration inaccuracy or formulation quality than to the salt form of the API. A prescriber familiar with GLP-1 pharmacology can help evaluate whether your experience is consistent with the documented effects of semaglutide at the prescribed dose.

The Current Status as of 2026

The base vs. salt controversy is, in some respects, now moot for semaglutide — the legal landscape has shifted in ways that make the salt-form argument largely academic.

Semaglutide compounding: largely ended. Shortage Resolved FDA removed semaglutide products from the shortage list in early 2025. By 2026, 503B outsourcing facilities no longer bulk-compound semaglutide under the shortage exception, and most 503A pharmacies have ceased offering it. The salt-form argument as a basis for continued compounding after shortage list removal did not carry the day in FDA enforcement or in the litigation that followed.

Tirzepatide compounding: still available but evolving. Verify Current Status Tirzepatide products remained on the shortage list longer than semaglutide products, and as of mid-2026, compounded tirzepatide is still available through many 503A pharmacies and some 503B facilities. The parallel litigation track on tirzepatide is still evolving. Availability may change as FDA makes further shortage determinations.

The legacy question for semaglutide patients: Patients who used compounded semaglutide during the 2022–2025 period and are now wondering whether they received a legitimate product have a reasonable answer available from the science: the active molecule was functionally equivalent semaglutide, and the quality of what they received was primarily determined by the pharmacy's quality practices, not by the salt form. The regulatory debate about what the shortage list covered was a legal and nomenclature dispute — not a scientific finding that the preparations patients received were pharmacologically inert or inferior.

On the ongoing tirzepatide litigation: The Outsourcing Facilities Association and related parties continued to litigate FDA's tirzepatide enforcement posture as of 2025–2026. The procedural and substantive questions in those cases bear on the continued availability of compounded tirzepatide. Patients and prescribers should monitor the current regulatory status rather than relying on any fixed assessment — this area remains genuinely in motion.

Frequently Asked Questions

Is semaglutide acetate the same as semaglutide base?

Pharmacologically, yes — once dissolved in body fluids, both release the same active semaglutide peptide. A salt form is the parent molecule paired with a counterion; upon dissolution, the counterion dissociates and the active molecule is identical regardless of which salt was used. This is a fundamental principle of pharmaceutical salt chemistry. Where base and salt forms can differ is in physical properties like solubility, stability, and hygroscopicity — differences that matter for compounding quality but not for the identity of the active molecule the patient receives.

Was compounded semaglutide made from a different drug than Ozempic?

Not in any pharmacologically meaningful sense. The active ingredient in Ozempic and Wegovy is semaglutide — a specific GLP-1 receptor agonist peptide. Compounded preparations, whether using semaglutide base, sodium, or acetate, contained the same semaglutide peptide as the active molecule. The FDA-approved NDAs specify particular formulation characteristics beyond just the active ingredient — the excipients, pH, buffer system, and delivery mechanism differ from most compounded versions — but the active molecule is not a different drug. The salt form question is about the counterion, not about whether the peptide itself is semaglutide.

Why did the FDA object to semaglutide sodium and acetate in compounding?

FDA's primary argument operated on two levels. First, the shortage list designation referred to semaglutide in its compendially designated (free acid / base) form, and salt forms were technically distinct chemical entities not separately listed on the shortage list. Second, when some compounders argued that using a salt form allowed them to avoid the "essentially a copy" prohibition even after semaglutide left the shortage list, FDA rejected this — its longstanding position is that a drug and its pharmacologically equivalent salts are the same active ingredient, and the copy prohibition applies to the active ingredient regardless of counterion. FDA characterized the salt-form distinction as a nomenclature argument inconsistent with established pharmaceutical science and regulatory practice.

Does the salt form of semaglutide affect how well it works?

The available pharmacological evidence suggests the salt form itself does not materially affect therapeutic activity. After dissolution and absorption, the active peptide is the same regardless of counterion. What can affect efficacy and safety are compounding quality factors that surround the active molecule: concentration accuracy, sterility, stability of the preparation, and formulation compatibility. These are quality-of-compounding issues, not salt-form issues. The meaningful risks in compounded semaglutide were about whether the pharmacy had rigorous quality controls, validated concentrations, and proper sterile technique — not about whether the API was the base or a salt.

Should patients who used compounded semaglutide be concerned?

Patients who received compounded semaglutide from a reputable licensed pharmacy during the shortage period should not be alarmed by the base vs. salt chemistry debate. The pharmacological evidence supports that the active molecule was functionally equivalent semaglutide regardless of salt form. The real quality concerns about compounded semaglutide — concentration accuracy, sterility, stability — are real but are about compounding practices, not the salt form. If you received compounded semaglutide from a pharmacy that provided third-party Certificate of Analysis documentation and operated as a licensed 503A or registered 503B facility, there is no specific clinical basis for concern arising from the salt-form question alone. If you have clinical concerns about your experience, discuss them with your prescriber.

Disclaimer: This article is written by an attorney for general informational and educational purposes only. It does not constitute legal advice, medical advice, or pharmacological guidance, and does not create an attorney-client relationship. The regulatory and legal landscape described reflects the state of affairs as of May 2026 and is subject to change — regulatory determinations, litigation outcomes, and enforcement postures can shift. This article describes FDA's stated positions and arguments made in litigation as reported; it does not represent those positions as legally conclusive for any specific situation. Always consult your prescriber regarding your specific medical situation, and consult a licensed pharmacist or attorney regarding any specific regulatory or legal questions. BetterNewLives.com is not affiliated with any compounding pharmacy, telehealth platform, pharmaceutical manufacturer, or party to the litigation described herein.